Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY II: Early Fecal Calprotectin Measurement to Prevent Crohn's Disease Recurrence
NCT06972901Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Randomised, open-label trial in Crohn's disease (2 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Postoperative endoscopic recurrence at 6 months. Started Oct 2025; status: recruiting.
02
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06972901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972901.